- •
The burden of heart failure is projected to increase over the next decade, and it is predicted that 1 in every 33 Americans will be affected by heart failure.
- •
The recent addition of the combination of sacubitril/valsartan (LCZ696) to guideline-directed medical therapies should ameliorate this burden.
- •
Neprilysin inhibition is associated with significant improvements in survival.
- •
Despite substantial reductions in mortality with neprilysin inhibition, the mortality rate among patients with heart
Sacubitril/Valsartan: The Newest Neurohormonal Blocker for Guideline-Directed Medical Therapy for Heart Failure
Section snippets
Key points
Pharmacology
Sacubitril, a prodrug, is an inhibitor of neprilysin, a neutral endopeptidase, that is responsible for degradation of biologically active vasoactive peptides, including natriuretic peptides (brain natriuretic peptide [BNP] and N-terminal [NT]-proBNP) and bradykinin (Figs. 1 and 2). ProBNPs convert into NT-proBNP and BNP. BNP acts by natriuresis, diuresis, vasodilatation, antiproliferative vascular effects, and decreased sympathetic tone. Degradation of BNP into breakdown products is inhibited
Neurohormonal blockade
The Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF3) showed that more patients in New York Heart Association (NYHA) class 2 and class 3 die of sudden death (Fig. 3). In NYHA class 2, 64% died of sudden death; in NYHA class 3, 59% died of sudden death; in class 2 only 12% died of systolic heart failure; in class 3 only 26% died of pump function or heart failure. In NYHA class 4, 56% died of loss of pump function or heart failure; only 33% died of sudden
Summary
Neprilysin inhibition is associated with significant improvements in survival. Despite substantial reductions in mortality with neprilysin inhibition, the mortality rate among patients with heart failure remains high around 20% over 2 years in the intervention arm of PARADIGM-HF, suggesting that opportunities to reduce mortality in heart failure remain.
References (27)
- et al.
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors
J Am Coll Cardiol
(2002) - et al.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
Lancet
(2003) - et al.
Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial
J Card Fail
(2005) - et al.
Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
Lancet
(2010) - et al.
Heart disease and stroke statistics-2017 update: a report from the American Heart Association
Circulation
(2017) - et al.
Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association
Circ Heart Fail
(2013) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
Lancet
(1999)- et al.
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
N Engl J Med
(1991) - et al.
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
N Engl J Med
(2001) - et al.
A meta-analysis of the effect of angiotensin-converting enzyme inhibitors on functional capacity in patients with symptomatic left ventricular systolic dysfunction
Eur J Heart Fail
(2004)
Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) programme
Eur Heart J
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
N Engl J Med
Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF
Circ Heart Fail
Cited by (2)
Effect of sacubitril/valsartan on the patients with cardiac insufficiency after acute myocardial infarction
2020, Chinese Journal of Clinical ResearchBasic Knowledge of Pharmacology
2019, Basic Knowledge of Pharmacology
Disclosure: The author has nothing to disclose.